RxSight, Inc. (NASDAQ: RXST) reported preliminary second-quarter 2026 revenue of approximately $32 million to $34 million, which includes $5 million to $7 million recognized from its strategic collaboration agreement with Alcon, according to a company statement.

Sales for the quarter totaled approximately $27 million, with 24,917 Light Adjustable Lens (LAL) units and 11 Light Delivery Device (LDD) units sold, plus one rental unit placed. The company held approximately $209 million in cash, cash equivalents, and short-term investments as of June 30, 2026.

RxSight revised its full-year 2026 sales guidance to $110 million to $120 million, down from a prior range of $120 million to $135 million, citing competitive trialing pressures. Total 2026 revenue guidance, including collaboration agreement revenue of $30 million to $40 million, stands at $140 million to $160 million. Gross margin guidance was raised to 73% to 75%, from a previous range of 70% to 72%, while operating expenses are expected at the high end of $150 million to $160 million.

The company said it plans to accelerate investment in its sales force and commercial capabilities. RxSight is developing next-generation versions of its LAL, LAL+, and LAL Toric lenses, which are designed to offer improved workflow and fewer required post-operative treatments. The Alcon collaboration targets development and commercialization of light-adjustable presbyopia-correcting intraocular lenses.

"While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing, the unique ability of RxSight's Light Adjustable Technology to customize visual outcomes continued to deliver significant clinical benefits to thousands of patients around the world," said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight.

RxSight noted the preliminary figures remain subject to completion of its financial statements and review by its independent registered public accounting firm. Full second-quarter results are expected after market close on August 5, 2026.